Luxna Biotech
Funding Series
Series B
Funding Amount
¥240m
[data from INITIAL 2024 Dec]
Healthcare/Medtech

About

With the goal of providing “drugs that bring light to patients a​nd their supporters,” Luxna Biotech is conducting both joint development with pharmaceutical companies a​nd in-house drug research using a nucleic acid drug research platform based on artificial nucleic acids developed at the Osaka University Graduate School of Pharmaceutical Sciences.

Milestone

By 2026, Luxna Biotech aims to initiate non-clinical trials for joint development programs with multiple pharmaceutical companies as well as in-house development programs, demonstrating the efficacy of nucleic acid medicines in treating neurological diseases. It also aims to secure a global presence and pursue an early IPO.
Visit Site
We're Here to Help
Have questions? Not sure where to start? Send us an email and let’s chat!
Email Us
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.